Author Archives: kbp admin

First CKD Patient in Phase IIa Trial Received KBP-5074

(Jinan, China, and Princeton, NJ) KBP BioSciences, a clinical stage biopharma company announced today that the first patient with chronic kidney disease has received its lead compound, KBP-5074 in a Phase Ib/IIa trial. Millions of people suffer from chronic kidney disease (CKD) and end stage renal disease (ESRD), which causes not only significant suffering of the

Read More

First Healthy Volunteer Received Single Dose KBP-7072

Jinan, China and Princeton, New Jersey, USA (May 5, 2015) KBP BioSciences, a clinical stage biotech company with operations in China, US, and Singapore, today announced that the first healthy volunteer had received first dose of KBP-7072. KBP-7072 is effective against a broad spectrum of bacteria in vitro. Bacteria resistance to antibiotics has been on

Read More

KBP BioSciences submitted IND of KBP-7072 to the cFDA

Jinan, China and Princeton, New Jersey, USA (May 2015) KBP BioSciences, a clinical stage biotech company with operations in China, US, and Singapore, today announced that the China FDA (cFDA) accepted an Initial New Drug Application (IND) for its experimental drug KBP-7072 for the potential treatment of serious bacterial infections. KBP-7072 is a next generation

Read More

The US FDA approved KBP-5074 to enter clinical trial

Jinan, China and Princeton, New Jersey, USA (Feb 10, 2014) KBP BioSciences, a clinical stage biotech company with operations in China, US, and Singapore, today announced that the US FDA approved KBP-5074 to enter clinical trials for the potential treatment of chronic kidney disease (CKD). This is KBP’s first clinical project in the US. Roughly

Read More